Ganaxolone

CAS 38398-32-2 1 current recordSmall Molecule

Who holds supplier records for Ganaxolone? 1 organisation holds a current record for Ganaxolone: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: Spain (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Ganaxolone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ganaxolone

Reading the evidence

  • One current record

    One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.

  • 1 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Ganaxolone expires 30 Sept 2042. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (1)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Ganaxolone. Country is the organisation's recorded country, not necessarily the manufacturing site.

  • CURIA SPAIN SAU
    Active DMF 43695 · latest filing Mar 2026
    Spain Company GMP cert on record
Need Ganaxolone sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Ganaxolone). The latest listed patent expires 30 Sept 2042. The latest listed exclusivity runs to 1 Jun 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Ganaxolone is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1568698).

Chemical identity

IUPAC name
1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
Canonical SMILES
CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C
InChIKey
PGTVWKLGGCQMBR-FLBATMFCSA-N
Synonyms
CCD 1042, CCD-1042, CCD1042, DEA NO. 2401, Ganaxolona, Ganaxolone, Ztalmy, ganaxolonum, RefChem:57127, C22H36O2, Ganaxolone [USAN], Ganaxolone [USAN:INN]

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Mechanism of action
GABA A Receptor Positive Modulators

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Ganaxolone?

1 organisation holds an active US FDA Type II Drug Master File or a CEP for Ganaxolone: CURIA SPAIN SAU (Spain). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Ganaxolone Drug Master Files are active?

CURIA SPAIN SAU (DMF 43695). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Ganaxolone?

Yes. The latest patent listed for an approved US product containing Ganaxolone expires 30 Sept 2042, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Ganaxolone supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Ganaxolone?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.